Advertisement

Agents and Actions

, Volume 29, Issue 3–4, pp 315–323 | Cite as

Effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis of mice

  • G. W. Cannon
  • S. McCall
  • B. C. Cole
  • M. M. Griffiths
  • L. A. Radov
  • J. R. Ward
Inflammation and Immunomodulation

Abstract

The long term effects of indomethacin, cyclosporin, cyclophosphamide, and placebo on collagen-induced arthritis in mice were tested under two different treatment protocols. A prophylactic experiment examined the effects of the daily drug administration for 180 days beginning one day before the first collagen injection. Under this dosage schedule, cyclophosphamide and cyclosporin decreased the severity of arthritis, while indomethacin did not. A therapeutic protocol examined the effects of these same drugs when daily administration was delayed until the animals had active disease at 78 days after the first collagen injection. Under this protocol, all three drugs reduced the progression of disease. In both protocols, the most significant suppression of arthritis was seen in animals receiving cyclophosphamide which was associated with a decrease in anti-collagen antibody levels. Collagen-induced arthritis in mice should be further investigated as a model to study the long term effects of “slow-acting” anti-rheumatic drugs.

Keywords

Placebo Arthritis Cyclosporin Cyclophosphamide Indomethacin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    P. H. Wooley, H. S. Luthra, J. M. Stuart and C. S. David,Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I relgion) linkage and antibody correlates. J. Exp. Med.154, 688–700 (1981).CrossRefPubMedGoogle Scholar
  2. [2]
    M. Cremer,Type II collagen-induced arthritis in rats. InHandbook of Animal Models for the Rheumatic Disease. Volume 1 (Eds. R. A. Greenwald and H. S. Diamond) pp. 17–27, CRC Press, Boca Raton, Florida 1988.Google Scholar
  3. [3]
    J. M. Stuart, L. K. Myers, A. S. Townes and A. H. Kang,Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J. Clin. Invest.69, 673–683 (1982).PubMedGoogle Scholar
  4. [4]
    J. S. Courtenay, M. J. Dallman, A. D. Dayan, A. Martin and B. Mosedale,Immunisation against heterologous type II collagen induces arthritis in mice. Nature283, 666–668 (1980).CrossRefPubMedGoogle Scholar
  5. [5]
    M. M. Griffiths, E. J. Eichwald, J. H. Martin, C. B. Smith and C. W. DeWitt,Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arth. Rheum.24, 781–789 (1981).Google Scholar
  6. [6]
    M. M. Griffiths and C. W. DeWitt,Immunogenetic control of experimental collagen-induced arthritis in rats. II. ECIA susceptibility and immune response to type II collagen (calf) are linked to RT1. J. Immunogen.8, 463–470 (1981).Google Scholar
  7. [7]
    J. S. Garvey, N. E. Cremer and D. H. Sussdorf,Methods in Immunology: a lab text for instruction and research. (3rd edition) pp. 301–312, The Benjamin cummings Publishing Company, Reading, MA, 1977.Google Scholar
  8. [8]
    K. Phadke, R. L. Fouts, J. E. Parrish and L. D. Butler,Evaluation of the effects of various anti-arthritic drugs on type II collagen-induced mouse arthritis model. Immunopharm.10, 51–60 (1985).CrossRefGoogle Scholar
  9. [9]
    C. Rordorf, A. Pataki, V. Nogues, F. Schlager, U. Feige and M. Glatt,Arthritis in MRL/lpr mice and in collagen II sensitized DBA-1 mice and their use in pharmacology. Int. J. Tiss.9, 341–347 (1987).Google Scholar
  10. [10]
    W. Paska, K. J. McDonald and M. Croft,Studies on type II collagen induced arthritis in mice. Agents and Actions18, 413–420 (1986).PubMedGoogle Scholar
  11. [11]
    A. E. Sloboda, J. E. Birnbaum, A. L. Oronsky and S. S. Kerwar,Studies on type II collagen-induced polyarthritis in rats. Effects of anti-inflammatory and anti-rheumatic agents. Arthritis and Rheum.24, 616–624 (1981).Google Scholar
  12. [12]
    K. Takagishi, N. Kaibara, T. Hotokebuchi, C. Arita, M. Morinaga and K. Arai,Effects of cyclosporin on collagen induced arthritis in mice. Ann. Rheum. Dis.45, 339–344 (1986).PubMedGoogle Scholar
  13. [13]
    N. Kaibara, T. Hotokebuchi, K. Takagishi, I. Katsuki, M. Morinaga, C. Arita and S. Jingushi,Pathogenetic difference between collagen arthritis and adjuvant arthritis. J. Exp. Med.159, 1388–1396 (1984).CrossRefPubMedGoogle Scholar
  14. [14]
    J. T. Hom, L. D. Butler, P. E. Riedl and A. M. Bendele,The progression of the inflammation in established collagen-induced arthritis can be altered by treatment with immunological or pharmacological agents which inhibit T-cell activities, Eur. J. Immunol.18, 881–888 (1988).PubMedGoogle Scholar
  15. [15]
    A. W. Probert Jr., D. J. Schrier and R. B. Gilbertsen,Effects of Antiarthritic compounds on type II collagen-induced arthritis in rats. Arch. Int. Pharm.269, 167–176 (1984).Google Scholar
  16. [16]
    A. J. Lewis, R. P. Carlson, J. Chang and F. DeLustro,Effect of gold salts, d-penicillamine and benoxaprofen on type II collagen-induced arthritis in rats. Agents and Actions14, 707–714 (1984).PubMedGoogle Scholar
  17. [17]
    K. Phadke, J. Carroll and S. Nanda,Effects of various anti-inflammatory drugs on type II collagen-induced arthritis in rats. Clin. Exp. Immun.47, 579–586 (1982).PubMedGoogle Scholar
  18. [18]
    S. S. Kerwar and A. E. Sloboda,Studies on the effect of fenbufen and sulindac on type II collagen-included arthritis in rats. Agents and Actions12, 216–220 (1982).CrossRefPubMedGoogle Scholar
  19. [19]
    N. Seki, Y. Sudo, T. Yoshioka, S. Sugihara, T. Fujitsu, S. Sakuma, T. Ogawa, T. Hamaoka, H. Senoh and H. Fujiwara,Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J. Immunol.140, 1477–1484 (1988).PubMedGoogle Scholar
  20. [20]
    R. Holmdahl, L. Klareskog, K. Rubin, E. Larsson and H. Wigzell,T-Lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scan. J. Immun.22, 295–306 (1985).Google Scholar
  21. [21]
    P. H. Wooley, H. S. Luthra, C. H. Krco, J. M. Stuart and C. S. David,Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of antitype II collagen antibody or free native type II collagen.Arthritis and Rheum. 27, 1010–1017 (1984).Google Scholar
  22. [22]
    J. M. Stuart, L. K. Myers, A. S. Townes and A. H. Kang,Effect of cyclophosphamide, hydrocortisone, and levamisole on collagen-induced arthritis in rats. Arthritis and Rheum.24, 790–794 (1981).Google Scholar

Copyright information

© Birkhäuser Verlag 1990

Authors and Affiliations

  • G. W. Cannon
    • 1
    • 2
    • 3
  • S. McCall
    • 4
    • 1
  • B. C. Cole
    • 5
    • 1
  • M. M. Griffiths
    • 6
    • 1
  • L. A. Radov
    • 7
    • 1
  • J. R. Ward
    • 8
    • 1
  1. 1.Division of Rheumatology, Department of Internal MedicineUniversity of Utah School of Medicine and Medical Service, Veterans Administration Medical CenterSalt Lake CityUSA
  2. 2.Division of RheumatologyUniversity of UtahSalt Lake CityUSA
  3. 3.VA Medical CenterSalt Lake CityUSAUSA
  4. 4.Laboratory SpecialistUniversity of UtahSalt Lake CityUSA
  5. 5.Division of RheumatologyUniversity of UtahSalt Lake CityUSA
  6. 6.Division of RheumatologyUniversity of Utah and Research Chemist, VA Medical CenterSalt Lake CityUSA
  7. 7.Pharmaceutical DivisionPennwalt CorporationRochesterUSA
  8. 8.Division of RheumatologyUniversity of UtahUSA

Personalised recommendations